Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study.
Alessandro OttaianoMariachiara SantorsolaFrancesco PerriVincenza GranataMarco CascellaFrancesco SabbatinoGuglielmo NastiPublished in: Journal of clinical medicine (2023)
we found a significant difference in terms of survival in favor of the TR sequence of treatment. Larger studies are needed to confirm these data and explore specific biomarkers predicting the correct sequence of oral drugs in the treatment of refractory mCRC patients.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- healthcare
- primary care
- newly diagnosed
- chronic kidney disease
- ejection fraction
- combination therapy
- peritoneal dialysis
- prognostic factors
- machine learning
- amino acid
- patient reported outcomes
- free survival
- quality improvement
- artificial intelligence
- data analysis